Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raltitrexed: current clinical status and future directions.

E Van Cutsem1, D Cunningham, J Maroun

  • 1Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium. eric.vancutsem@uz.kuleuven.ac.be

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|June 12, 2002
PubMed
Summary

Raltitrexed offers a convenient alternative to 5-fluorouracil for advanced colorectal cancer. Combinations with other agents show promise for various solid tumors, including mesothelioma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital health technology in oncology: results from a survey by the ESMO Young Oncologists Committee and medical student alumni.

ESMO real world data and digital oncology·2026
Same author

Opportunities and challenges in implementing digital patient-centred cancer care in Europe-a qualitative study of several ESMO Designated Centres.

ESMO real world data and digital oncology·2026
Same author

Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study.

ESMO open·2026
Same author

Gastric cancer hospital-based registry: real-world gastric cancer data from Latin America and Europe.

ESMO gastrointestinal oncology·2026
Same author

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

ESMO open·2025
Same author

Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons.

ESMO open·2025

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Raltitrexed (Tomudex) is a thymidylate synthase inhibitor used as monotherapy for advanced colorectal cancer (CRC).
  • It presents a distinct mechanism of action and toxicity profile compared to 5-fluorouracil (5-FU).
  • Raltitrexed's unique properties suggest potential for combination therapies.

Purpose of the Study:

  • To review the management of patients treated with raltitrexed, both as monotherapy and in combination.
  • To discuss preliminary results of raltitrexed combination studies across various solid tumors.
  • To highlight the potential of raltitrexed-based regimens in advanced cancers.

Main Methods:

  • Review of clinical data and preclinical studies involving raltitrexed.
  • Analysis of combination therapies including raltitrexed with 5-FU, other chemotherapeutics, and radiotherapy.

Related Experiment Videos

  • Focus on outcomes in advanced colorectal cancer and malignant mesothelioma.

    • Main Results:

    • Raltitrexed monotherapy is a viable alternative to 5-FU in first-line advanced CRC treatment.
    • Combination studies demonstrated promising antitumour effects, particularly raltitrexed with oxaliplatin.
    • Positive preliminary results were observed in advanced CRC and chemotherapy-refractory malignant mesothelioma.

    Conclusions:

    • Raltitrexed-based combinations may offer improved therapeutic options for advanced solid tumors.
    • The combination of raltitrexed and oxaliplatin shows significant potential in treating advanced CRC and mesothelioma.
    • Further investigation into raltitrexed combinations is warranted for various advanced malignancies.